New and emerging treatments for symptomatic tardive dyskinesia

References

• Paulsen JS Heaton RK Jeste DV Neuropsychological impairment in tardive dyskinesia Neuropsychology 1994 8 2 227 241
   Google Scholar
• Rao AS Camilleri M Review article: metoclopramide and tardive dyskinesia Aliment Pharmacol Ther 2001 31 1 11 19 19886950
   PubMed Web of Science ®Google Scholar
• Goldberg RJ Tardive dyskinesia in elderly patients: an update J Am Med Dir Assoc 2002 3 3 152 161 12807659
   PubMedGoogle Scholar
• Rosenheck RA Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics Br J Psychiatry 2007 191 238 245 17766765
   PubMed Web of Science ®Google Scholar
• Saltz BL Robinson DG Woerner MG Recognizing and managing antipsychotic drug treatment side effects in the elderly Prim Care Companion J Clin Psychiatry 2004 6 Suppl 2 14 19 16001096
   PubMedGoogle Scholar
• Mentzel CL Tenback DE Tijssen MA Visser-Vandewalle VE van Harten PN Efficacy and safety of deep brain stimulation in patients with medication-induced tardive dyskinesia and/or dystonia: a systematic review J Clin Psychiatry 2012 73 11 1434 1438 23218160
   PubMed Web of Science ®Google Scholar
• Woods SW Morgenstern H Saksa JR Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study J Clin Psychiatry 2010 71 4 463 474 20156410
   PubMed Web of Science ®Google Scholar
• Lee PE Sykora K Gill SS Antipsychotic medications and drug-induced movement disorders other than Parkinsonism: a population-based cohort study in older adults J Am Geriatr Soc 2005 53 8 1374 1379 16078964
   PubMed Web of Science ®Google Scholar
• de Leon J The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study Eur Arch Psychiatry Clin Neurosci 2007 257 3 169 172 17149539
   PubMed Web of Science ®Google Scholar
• Ragheb MM Goldberg RJ Tardive dyskinesia in geriatric patients Aging Health 2006 2 5 833 849
   Google Scholar
• Teo JT Edwards MJ Bhatia K Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis Mov Disord 2012 27 10 1205 1215 22865512
   PubMed Web of Science ®Google Scholar
• Thelma B Srivastava V Tiwari AK Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics Pharmacogenomics 2008 9 9 1285 1306 18781856
   PubMed Web of Science ®Google Scholar
• Muller DJ Chowdhury NI Zai CC The pharmacogenetics of antipsychotic-induced adverse events Curr Opin Psychiatry 2012 26 2 144 150 23370274
   PubMed Web of Science ®Google Scholar
• Seeman P All psychotic roads lead to increased dopamine D2high receptors: a perspective Clin Schizophr Relat Psychoses 2008 1 4 351 355
   Google Scholar
• Ito H Takano H Takahashi H Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission? J Neurosci 2009 29 43 13730 13734 19864585
   PubMed Web of Science ®Google Scholar
• Seeman P Targeting the dopamine D2 receptor in schizophrenia Expert Opin Ther Targets 2006 10 4 515 531 16848689
   PubMed Web of Science ®Google Scholar
• Remington G Kapur S Antipsychotic dosing: how much but also how often? Schizophr Bull 2010 36 5 900 903 20650931
   PubMed Web of Science ®Google Scholar
• Ginovart N Wilson A Hussey D Houle S Kapur S D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats Neuropsychopharmacology 2008 34 3 662 671 18688210
   PubMed Web of Science ®Google Scholar
• Stephenson CM Bigliani V Jones HM Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography (SPET) study Br J Psychiatry 2000 177 408 415 11059993
   PubMed Web of Science ®Google Scholar
• Creed-Carson M Oraha A Nobrega JN Effects of 5-HT2A and 5-HT2C receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats Behav Brain Res 2011 219 2 273 279 21262266
   PubMed Web of Science ®Google Scholar
• Grimm JW Chapman MA Zahm DS See RE Decreased choline acetyl-transferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats Synapse 2001 39 1 51 57 11071709
   PubMed Web of Science ®Google Scholar
• Kelley JJ Roberts RC Effects of haloperidol on cholinergic striatal interneurons: relationship to oral dyskinesias J Neural Transm 2004 111 8 1075 1091 15254795
   PubMed Web of Science ®Google Scholar
• Andreassen OA Ferrante RJ Aamo TO Beal MF Jørgensen HA Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats Neuroscience 2003 122 717 725 14622915
   PubMed Web of Science ®Google Scholar
• Pappa S Tsouli S Apostolou G Mavreas V Konitsiotis S Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled trial Clin Neuropharmacol 2010 33 6 271 275 21121175
   PubMed Web of Science ®Google Scholar
• Ethier I Kagechika H Shudo K Rouillard C Lévesque D Docosahexaenoic acid reduces haloperidol-induced dyskinesias in mice: involvement of Nur77 and retinoid receptors Biol Psychiatry 2004 56 522 526 15450789
   PubMed Web of Science ®Google Scholar
• Mahmoudi S Blanchet P Levesque D Haloperidol-induced striatal Nur77 expression in a non-human primate model of tardive dyskinesia Eur J Neurosci 2013 38 1 2192 2198 23551242
   PubMed Web of Science ®Google Scholar
• Novak G Gallo A Zai CC Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia Psychiatr Genet 2010 20 1 39 43 20010315
   PubMed Web of Science ®Google Scholar
• Margolese HC Chouinard G Kolivakis TT Beauclair L Miller R Annable L Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia Can J Psychiatry 2005 50 11 703 714 16363464
   PubMed Web of Science ®Google Scholar
• Busanello A Barbosa N Peroza L Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice Behav Pharmocol 2011 22 1 71 75
   Web of Science ®Google Scholar
• Busanello A Peroza L Wagner C Resveratrol reduces vacuous chewing movements induced by acute treatment with fluphenazine Pharmacol Biochem Behav 2012 101 2 307 310 22266770
   PubMed Web of Science ®Google Scholar
• van Harten PN Hovestadt A Botulinum toxin as a treatment for tardive dyskinesia Mov Disord 2006 21 8 1276 1277 16671083
   PubMed Web of Science ®Google Scholar
• Slotema CW van Harten PN Bruggeman R Hoek HW Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study Prog Neuropsychopharmacol Biol Psychiatry 2008 32 2 507 509 18022743
   PubMed Web of Science ®Google Scholar
• Zhang WF Tan YL Zhang XY Chan RC Wu HR Zhou DF Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial J Clin Psychiatry 2011 72 5 615 621 20868638
   PubMed Web of Science ®Google Scholar
• Howland RH Drug therapies for tardive dyskinesia: Part 1 J Psychosoc Nurs Ment Health Serv 2011 49 6 13 16
   Web of Science ®Google Scholar
• Guay DR Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders Am J Geriatr Pharmacother 2010 8 4 331 373 20869622
   PubMed Web of Science ®Google Scholar
• Kenney C Hunter C Jankovic J Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders Mov Disord 2007 22 2 193 197 17133512
   PubMed Web of Science ®Google Scholar
• Thaker GK Nguyen JA Strauss ME Jacobson R Kaup BA Tamminga CA Clonazepam treatment of tardive dyskinesia: A practical gabamimetic strategy Am J Psychiatry 1990 147 7 445 451 1969244
   PubMed Web of Science ®Google Scholar
• Howland RH Drug therapies for tardive dyskinesia: Part 2 J Psychosoc Nurs Ment Health Serv 2011 49 7 17 20
   Web of Science ®Google Scholar
• Littrell K Magill A The effect of clozapine on preexisting tardive dyskinesia J Psychosoc Nurs Ment Health Serv 1993 31 9 14 19 7901407
   PubMedGoogle Scholar
• Bassitt DP Louzã Neto MR Clozapine efficacy in tardive dyskinesia in schizophrenic patients Eur Arch Psychiatry Clin Neurosci 1998 248 4 209 211 9810484
   PubMed Web of Science ®Google Scholar
• Louzã MR Bassitt DP Maintenance treatment of severe tardive dyskinesia with clozapine 5 years’ follow-up J Clin Psychopharmacol 2005 25 2 180 182 15738751
   PubMed Web of Science ®Google Scholar
• Castro F Carrizo E Prieto de Rincón D Effectiveness of melatonin in tardive dyskinesia Invest Clin 2011 52 3 252 260 21950196
   PubMed Web of Science ®Google Scholar
• Shamir E Barak Y Plopsky I Zisapel N Elizur A Weizman A Is melatonin treatment effective for tardive dyskinesia? J Clin Psychiatry 2000 61 6 556 558 10982197
   PubMed Web of Science ®Google Scholar
• Nelson K Mcguire J Hausafus S Melatonin for the treatment of tardive dyskinesia Ann Pharmacother 2003 37 7–8 1128 1131 12841828
   PubMed Web of Science ®Google Scholar
• Lerner V Miodownik C Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment Curr Psychiatry Rep 2011 13 4 295 304 21519907
   PubMed Web of Science ®Google Scholar
• Vaddadi K Hakansson K Clifford J Waddington J Tardive dyskinesia and essential fatty acids Int Rev Psychiatry 2006 18 2 133 143 16777667
   PubMed Web of Science ®Google Scholar
• Iwata Y Irie S Uchida H Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial J Neurol Sci 2012 315 1–2 137 140 22285275
   PubMed Web of Science ®Google Scholar
• Yamamura S Ohoyama K Nagase H Okada M Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway Neuropharmacology 2009 57 3 322 331 19482038
   PubMed Web of Science ®Google Scholar
• Lynch B Lambeng N Nocka K The synaptic vesicle protein SVA2 is the binding site for the antiepileptic drug levetiracetam Proc Natl Acad Sci U S A 2004 101 26 9861 9866 15210974
   PubMed Web of Science ®Google Scholar
• Woods SW Saksa JR Baker CB Cohen SJ Tek C Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study J Clin Psychiatry 2008 69 4 546 554 18312060
   PubMed Web of Science ®Google Scholar
• Konitsiotis S Pappa S Mantas C Mavreas V Levetiracetam in tardive dyskinesia: an open label study Mov Disord 2006 21 8 1219 1221 16637037
   PubMed Web of Science ®Google Scholar
• Emsley R Turner HJ Schronen J Botha K Smit R Oosthuizen PP A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia J Clin Psychiatry 2004 65 5 696 701 15163258
   PubMed Web of Science ®Google Scholar
• Richardson MA Bevans ML Read LL Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men Am J Psychiatry 2003 160 6 1117 1124 12777270
   PubMed Web of Science ®Google Scholar
• Richardson MA Small AM Read LL Chao HM Clelland JD Branched chain amino acid treatment of tardive dyskinesia in children and adolescents J Clin Psychiatry 2004 65 1 92 96 14744176
   PubMed Web of Science ®Google Scholar
• Kimiagar I Dobronevsky E Prokhorov T Miniovitz A Rabey JM Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study J Neurol 2012 259 4 660 664 22068977
   PubMed Web of Science ®Google Scholar
• Thobois S Poisson A Damier P Surgery for tardive dyskinesia Int Rev Neurobiol 2011 98 289 296 21907092
   PubMed Web of Science ®Google Scholar
• Welter ML Grabli D Vidailhet M Deep brain stimulation for hyperkinetics disorders: dystonia, tardive dyskinesia, and tics Curr Opin Neurol 2010 23 4 420 425 20610993
   PubMed Web of Science ®Google Scholar